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Background: Anorexia nervosa is a psychosomatic disease that affects many women worldwide. It is
commonly associated with comorbidities and has the highest mortality rate of any mental illness. Current
treatments are often insufficient in treating this disease and frequently fail to improve the health and quality of
life of these women. Deep brain stimulation (DBS) is an established treatment for neurological movement
disorders and is emerging as a treatment for psychological disorders similar to anorexia. Due to this similarity,
DBS may be an option for treating these women who fail other treatments. This review looks at the outcomes
of DBS as a treatment for anorexia nervosa.
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID,
CINAHL, and Web of Science using the keywords: deep brain stimulation, anorexia nervosa, and female.
Relevant articles were assessed for quality using GRADE.
Results: Through screening, three studies were found that fit the criteria for this review. This included three
observational studies. All three showed improved outcomes in the majority of subjects and demonstrated the
relative safety of the procedure. Outcomes included body mass index (BMI), vital signs, anxiety, depression,
obsessive-compulsion, quality of life, intelligence, memory, social functioning, brain glucose metabolism, and
adverse events associated with the surgery. Though the results of the three studies were promising, the overall
quality of the studies was very low. More research is needed to demonstrate the efficacy and safety of this
treatment and better understand its mechanism for treating this disorder.
Conclusion: DBS may play an important role in treating anorexia nervosa that has proven refractory to
standard treatments. DBS may be associated with improvement in physical symptoms, psychological
outcomes, and changes in brain glucose metabolism, but more research is needed to further examine this
association.
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Abstract 
Background: Anorexia nervosa is a psychosomatic disease that affects many women worldwide. 
It is commonly associated with comorbidities and has the highest mortality rate of any mental 
illness. Current treatments are often insufficient in treating this disease and frequently fail to 
improve the health and quality of life of these women. Deep brain stimulation (DBS) is an 
established treatment for neurological movement disorders and is emerging as a treatment for 
psychological disorders similar to anorexia. Due to this similarity, DBS may be an option for 
treating these women who fail other treatments. This review looks at the outcomes of DBS as a 
treatment for anorexia nervosa.  
 
Methods:  An exhaustive search of available medical literature was conducted using Medline-
OVID, CINAHL, and Web of Science using the keywords: deep brain stimulation, anorexia 
nervosa, and female. Relevant articles were assessed for quality using GRADE.  
 
Results: Through screening, three studies were found that fit the criteria for this review. This 
included three observational studies. All three showed improved outcomes in the majority of 
subjects and demonstrated the relative safety of the procedure. Outcomes included body mass 
index (BMI), vital signs, anxiety, depression, obsessive-compulsion, quality of life, intelligence, 
memory, social functioning, brain glucose metabolism, and adverse events associated with the 
surgery. Though the results of the three studies were promising, the overall quality of the studies 
was very low. More research is needed to demonstrate the efficacy and safety of this treatment 
and better understand its mechanism for treating this disorder.  
 
Conclusion: DBS may play an important role in treating anorexia nervosa that has proven 
refractory to standard treatments. DBS may be associated with improvement in physical 
symptoms, psychological outcomes, and changes in brain glucose metabolism, but more research 
is needed to further examine this association. 
 
Keywords: deep brain stimulation, anorexia nervosa, female 
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Outcomes of Deep Brain Stimulation on Adolescent and Adult 
Women with Refractory Anorexia Nervosa 
BACKGROUND 
 Anorexia nervosa (AN) affects up to 4% of women throughout the world in their 
lifetime.1 As a very common psychosomatic disorder, it is associated with high morbidity and 
mortality, yet is poorly understood. While it is very prevalent in the United States and other 
Western cultures, it is growing increasingly common in non-Western countries, such as China.2 
AN is defined in the DSM-V by the following criteria: restriction of energy intake relative to 
requirements, leading to a significantly low body weight in the context of age, sex, 
developmental trajectory, and physical health; intense fear of gaining weight or of becoming fat, 
or persistent behavior that interferes with weight gain, even though at a significantly low weight; 
and disturbance in the way in which one’s body weight or shape is experienced, undue influence 
of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of 
the current low body weight. Severity is measured by body mass index (BMI), with ≥17 kg/m3 
classified as mild, 16-16.99 kg/m3 as moderate, 15-15.99 kg/m3 as severe, and <15 kg/m3 as 
extreme.3 
Up to 24.3% of patients who have AN also suffer from a comorbidity, some of which are 
serious and life threatening.1 Comorbid conditions include osteoporosis, cardiac dysfunction, 
neurological deficits, renal dysfunction, other psychosomatic disorders, and suicide. This 
disorder along with its complications account for many office visits and hospitalizations, with 
Lipsman et al4 reporting a near combined 50 years of hospitalizations between its six subjects. 
With a mortality rate approaching 20%, it is the most deadly of all the psychosomatic disorders.  
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 While there are multiple methods currently used for the treatment of AN, many of them 
are deemed ineffective in a large percentage of patients. Conventional treatment efforts include 
pharmacotherapy and psychotherapy. Common medications used include SSRIs as first line 
therapy along with psychopharmaceuticals and the off-label use of neuroleptics such as 
olanzapine. However, these medications have been shown to have a weak effect at best.5 
Psychotherapy and self-help programs, such as family therapy and cognitive behavioral therapy, 
seem to be the most effective treatments for AN at this time.6-8 However, studies9-11 report that 
30% of AN patients that undergo these conventional treatments report little, if any, success while 
a mere 33% report full recovery. In addition, it has been shown that treatment by weight gain 
alone results in a faster relapse than if comorbid mood and anxiety symptoms are targeted.12-16   
Brain regions have been studied and corresponding glucose metabolism has been 
measured in order to determine patterns among women with AN. Patterns of increased or 
decreased metabolism have been observed in certain brain regions in subjects with psychological 
disorders. Similar patterns have been found in the subcallosal cingulate region in patients with 
AN as in patients with these other disorders (e.g., depression and anxiety).17-21 Examining and 
targeting these specific locations will be critical in designing DBS treatment for these patients.  
Furthermore, hypermetabolism of glucose has been noted across patients with AN in 
many areas, including the caudate nuclei, lateral inferior frontal cortex, thalamus and putamen.22 
In contrast, hypometabolism has been consistently noted in the parietal lobe. The frontal cortex 
has been associated with punishing stimuli23 and compulsive behaviors.24 The parietal cortex is 
the most consistently involved area in AN and may play a part in mood regulation25 and 
proprioception and visual information of one’s own body, possibly leading to altered self-
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perception of body image.26 The nucleus accumbens has been associated with the rewarding 
nature of the disorder and the physiological drive to eat.27 The lentiform nucleus has been 
connected to altered reward and affect, decision making, and executive control along with the 
stereotypic motor movements and decreased food ingestion associated with the disorder.28 The 
subcallosal cingulate has been connected to a negative affect due to decreased serotonin 
binding.18,19,29,30 The hippocampus and amygdala have been associated with the intense fear of 
weight gain, fearful emotional processing of negative words concerning body image,31 and their 
own fat image.32 Lastly, the insula is also associated with body image perception33 and altered 
interoceptive processing34, which could be associated with lack of recognition of the symptoms 
of malnutrition and diminished motivation to change.35  
Deep brain stimulation has been used for over 25 years4 and is an acceptable treatment 
for neurological movement disorders, such as Parkinson disease and essential tremor. Recent 
studies have shown that it may also be helpful in those with neuropsychiatric disorders, such as 
severe depression, obsessive-compulsive disorder, and other mood and anxiety disorders.36,37 
Due to similarities in these psychological disorders to AN, it is possible that DBS could offer an 
effective treatment for this often under-treated disorder. This systematic review looks at the 
research done in this area to evaluate its potential effectiveness and safety.     
METHODS 
 An exhaustive search of the medical literature was performed using Medline-OVID, 
CINAHL, and Web of Science. The following keywords were used: anorexia nervosa, deep brain 
stimulation, and female. Inclusion criteria included studies performed on women with a 
diagnosis of anorexia nervosa that had proven refractory to conventional treatment (including 
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pharmacotherapy, psychotherapy, hospital admissions, etc.). Exclusion criteria included studies 
in a language other than English, studies in which DBS was performed for a primary reason 
other than anorexia nervosa, or studies performed on subjects other than humans. Reviews and 
magazine articles were also excluded. Articles were evaluated for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) system38 and are 
included in this systematic review. 
RESULTS 
 The above search initially returned 11 articles for review. After employing the inclusion 
and exclusion criteria, three articles remained that are included in this systematic review. All 
three of these articles are observational studies. 
Wang et al 
 This study1 was a pre/postexperimental study designed to analyze the effects of 
stereotactic surgery on AN patients. Two of the eight subjects underwent DBS of the nucleus 
accumbens (NAc), while the other six underwent ablation of the same area. The two subjects that 
underwent DBS were 28 and 18 years old with illness durations of 2 and 3 years and amenorrhea 
durations of 5 and 9 months, respectively. Outcomes included vital signs, BMI, menstruation, 
depression, anxiety, obsessive-compulsive symptoms, quality of life, intelligence, and memory.1  
 All subjects were recruited from the Tangdu Hospital in China between January 2007 and 
December 2009. Patients were included if they had a DSM-IV diagnosis of AN that had lasted at 
least 2 years, were over 18 years of age, had shown resistance to standard treatments, were 
deemed as being in a life-threatening situation by their doctor, and were physically eligible for 
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elective neurosurgery. Exclusion criteria included the presence of any contraindications to 
surgery, metabolic pathology interfering with eating or digestion (e.g., diabetes), psychotic 
disorder, or an inability to understand the interview questions or sign the consent.1  
 A DBS electrode was implanted inside the targeted NAc and stimulation was started 2 
days after the surgery. The BMI of the two patients increased from 13.3 to 18.0 and 12.9 to 20.8 
by 1 year postoperatively. In addition, basic vital signs (blood pressure, heart rate, and 
temperature) improved significantly and menstruation returned within 9 months. These were 
probably affected in part by an increased physiological drive to eat. Depression, anxiety, 
obsessive-compulsive, and psychoticism scores decreased while intelligence, memory, quality of 
life, and social functioning scores increased (see Table II). A p-value of less than 0.05 was 
considered significant. Assessors and psychologists were blinded to the treatment.1  
Zhang et al 
 This observational study35, which followed a pre/postexperimental design, looked to 
demonstrate the changes in brain glucose metabolism following DBS. Given that DBS targeted 
at the NAc has been accepted as a treatment for obsessive-compulsive disorder (OCD) and that 
AN and OCD share common mechanisms, the authors hypothesized that there may be a common 
abnormal brain region that contributes to the symptoms of both disorders. Six AN patients and 
12 healthy controls were included in this study. Ages of the 6 subjects ranged from 13 to 17 and 
the duration of their disease ranged from 13 to 42 months. All were on at least one drug for their 
condition, including SSRIs, olanzapine, quetiapine, and aripiprazole. Outcomes included brain 
glucose metabolism, BMI and the need for drugs post-DBS.35 
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 The study was approved by the medical ethics committee of Fudan University Huashan 
Hospital and Shanghai Jiaotong University Ruijing Hospital, both in China. All subjects had 
been diagnosed with restricting type AN and had failed conventional therapies. Healthy controls 
were included for comparison of brain glucose metabolism if they did not have a current axis I 
psychiatric disorder, had not taken psychotropic medications or hormones within the past six 
months, and had no history of neurological disease, head injury, or alcohol abuse.35  
Glucose metabolism was examined via fludeoxyglucose (18F) positron emission 
tomography (18F-FDG PET) scans in the subjects. Four of the AN patients underwent NAc-DBS 
and had a follow-up scan three to six months after the surgery to assess changes. In the four AN 
patients that had DBS, glucose metabolism was found to decrease in the frontal lobe, bilateral 
lentiform nucleus, and hippocampus, which had been found to be the major differing areas from 
the healthy controls. In addition, BMI increased in all four subjects from a mean of 12.13 to 
15.65 at one month and no drugs were required post-DBS.35  
Lipsman et al 
 This study4 was a phase I prospective trial to examine the safety and efficacy of deep 
brain stimulation on patients with treatment-refractory anorexia nervosa. Six patients were 
included, ages 24-57. The duration of their illnesses ranged from 4 to 37 years. All but one had 
psychiatric comorbidities, such as major depressive disorder (MDD), OCD, and post-traumatic 
stress disorder (PTSD) and all six had medical complications, including cardiac, endocrine, 
gastrointestinal, musculoskeletal and metabolic problems. The primary outcomes of this study as 
a pilot trial were any adverse events associated with the procedure. Its purpose was to evaluate 
the safety of the procedure before recommending further research in that area. Secondary 
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outcomes included weight (BMI) and mood and anxiety measures (Beck depression inventory 
(BDI), Beck anxiety inventory (BAI), Hamilton depression rating scale 17 (HAMD), Yale-
Brown obsessive compulsive scale (YBOCS), and Yale-Brown-Cornell eating disorder scale 
(YBC-EDS)).4  
 Patients were recruited from Toronto General Hospital’s eating disorders program along 
with community referrals. Inclusion criteria included males and females ages 20-60 (only 
females qualified) diagnosed with restricting or binge-purge type anorexia nervosa showing 
chronicity or treatment resistance. Subjects were excluded if they had a history of psychosis, 
neurological diseases, or alcohol or substance abuse in the past 6 weeks, contraindications to 
MRI or PET scanning, BMI of less than 13, or pregnancy. Baseline psychometric assessments 
and BMI measurements were performed along with MRI and 18F-FDG PET neuroimaging.4  
 The subcallosal cingulate was the area of interest in this study due to similar patterns of 
activity shown across patients with other psychological disorders (e.g., depression, mood and 
anxiety disorders). This area was targeted with hopes that it would lead to a longer recovery than 
the treatment of weight alone, which has been shown to lead to a faster relapse. During the 
procedure, electrodes were inserted and an intraoperative AN rating scale designed by the 
research team was administered to monitor changes in symptoms with stimulation. They were 
placed in the areas that elicited the most relief from mood and anxiolytic symptoms or as near as 
possible to the subcallosal cingulate. The electrodes were then connected to a pulse generator, 
which was placed subcutaneously below the clavicle under general anesthesia.4  
 Several adverse events were noted during the study, the most serious being a seizure 
experienced two weeks postoperatively due to a metabolic derangement. The DBS device was 
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deactivated and turned back on 1 week later with no further problems. Other adverse events, 
including a panic attack, air embolus, and hypokalemia, were deemed non-study related and the 
procedure was considered to be safe. Three patients experienced pain associated with the surgical 
incision or positioning. At nine months, none of the subjects had experienced death, stroke, 
infection, or serious device-related complications.4  
In reference to other outcomes measured in this study, BMI increased to a healthy range 
in three of the six patients by 9 months. Overall mean scores on depression, OCD, anxiety, and 
eating disorder (ED) scales significantly decreased and quality of life increased. More 
specifically, quality of life increased in those who saw an increase in BMI.4 
DISCUSSION 
According to the above evidence, DBS significantly improved outcomes in women with 
refractory AN. The Wang et al study1 demonstrated the potential of DBS to increase the physical 
health, mental health, and cognitive level of the subjects and decrease common symptoms in AN. 
No serious adverse events were noted. The Zhang et al study35 shed some light on the neural 
pathways involved in the disordered behaviors of people with AN. It helped to better define 
which areas lead to specific symptoms of the disorder. Improvement in these areas offer promise 
in the way of treatment of refractory AN if these locations can be targeted. Finally, the Lipsman 
et al4 study showed that DBS as a treatment for AN is relatively safe and can lead to 
improvements in BMI and AN-associated symptoms. Most importantly, it demonstrated that 
DBS may disrupt important illness-maintaining factors and could be a solution for patients with 
refractory disease.  
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 The results of the aforementioned studies have shown to be consistent. Outcomes 
measured were not identical across all three, but the results of each study were supportive of the 
others. Outcomes measured improved overall across the board and can be divided into those that 
pertain to physical health, psychological health, glucose metabolism, and safety of the procedure. 
The increase in physical health was made clear in multiple studies (see Tables II and III). In the 
three studies evaluated in this systematic review, 9 of the 12 patients that received DBS had a 
significant increase in their BMI.1,4,35 In Wang et al1, vital signs returned to a normal range and 
menstruation returned within nine months. None of the four patients in Zhang et al35 required 
drugs after DBS, even though they had required them prior to the procedure.  
 Psychological health was also improved in the three studies examined (see Tables II and 
III). Symptoms of anxiety, depression, and obsession-compulsion were significantly 
decreased.1,4,35 These are aspects of the disorder that increase the behaviors typical of the 
disorder and significantly decrease the quality of life in patients with AN. Lipsman et al4 showed 
a positive effect of DBS on depression, anxiety, OCD, and ED symptoms. Wang et al1 showed a 
positive effect on depression anxiety, OCD, psychotic, and neurotic symptoms and showed 
increased intelligence, memory, social functioning, and quality of life.  
In addition, ten of the ten patients in which glucose metabolism was measured showed 
metabolic improvement in the targeted areas following DBS (see Tables II and III). These 
studies display important patterns of hyper- and hypometabolism. In addition, the changes that 
came with targeted DBS confirm the specificity of these patterns. These changes were 
appreciated as early as three to six months after the surgery.4,35 If the underlying cause of the 
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symptoms and behaviors of AN can be targeted, it is possible that the root of the problem can be 
reached.  
Lastly, only one of the patients that underwent DBS had a serious adverse effect that did 
resolve itself.4 This offers promising proof that DBS is a relatively safe procedure and may open 
the door for further studies to be completed.  
 The main limitations of these studies.1,4,25 included small sample sizes and a lack of 
control groups. The follow-up times in each study were short at 6 months,35 9 months,4 and 1 
year,1 limiting the confidence that the results are long-lasting. Although Lipsman et al4 had a 
control group, it was not an appropriate control group due to multiple variables and there was a 
lack of blinding in the study in order to maintain the safety of the patients. These limitations 
decrease the quality of the evidence but can be understood due to the high cost and invasiveness 
of DBS and the fact that these were pilot trials. Additionally, although the sample sizes were 
small, the treatment effect was quite significant, giving more credibility to the research. In 
addition, brain glucose metabolism, vital signs, and BMI as outcomes are very objective, also 
giving more validity to the research. Other outcomes, such as the mood scales, are more 
subjective, but showed a large treatment effect in most of the subjects. 
 One of the main concerns of these studies was the high cost of DBS. DBS generally costs 
between $35 000 and $50 000, with some bilateral procedures costing as much as $100 000 after 
accounting for anesthesia, hospital, device, and physician fees.39 However, inpatient treatment 
costs upward of $1000 per day to cover for staff (including medical providers, therapists, nurses, 
dietitians, care staff, etc.), meals, and housing. This often does not include medications, lab 
processing, and outside consults.40 Typically, patients require a stay of at least three to six 
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months, often returning for multiple stays with relapses. Though expensive, DBS may be more 
cost-effective in the long run and may get to the root of the problem faster than conventional 
treatments.  
 Further study in this area is recommended to continue to examine the effectiveness and 
safety of DBS in the treatment of AN. Randomized controlled trials with larger sample sizes are 
needed, especially now that the relative safety has been demonstrated. Comparisons can be made 
through RCTs between those receiving DBS and those receiving conventional treatments, 
although blinding may be difficult. The outcomes used in the studies in this review are fairly 
comprehensive given what is known about the effects of AN and could help show differences 
between the two treatments. Due to the large number of treatment centers in the United States, 
subjects could be recruited easily from inpatient centers or hospitals. Additionally, further study 
is needed to examine relationships between the response to DBS and patient demographics (e.g., 
age, duration of disorder, comorbid conditions, and type of AN). Further study of specific areas 
of the brain may also help better target the disorder in certain patients. Studies with longer 
follow-up times would also help determine whether or not the results are long-lasting. For 
example, one subject in the Lipsman et al4 study had suffered from this disorder for 37 years. 
Ideally, future studies could follow these subjects for 10, 20, or even 30 years postoperatively to 
determine whether or not the effects of DBS wear off against the chronicity of this disorder.  
CONCLUSION 
DBS significantly improved outcomes in adolescent and adult women with refractory 
anorexia nervosa. Outcomes measured included body weight (measured by BMI), vital signs, 
return of menstruation, brain glucose metabolism, depression, OCD, anxiety and ED scores, 
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intelligence, memory, quality of life, and adverse events associated with the surgery. DBS was 
shown to increase BMI and improve vital signs. In addition, it decreased many of the 
psychological symptoms associated with the disorder, such as depression, OCD, anxiety, and ED 
behaviors while displaying a positive effect on intelligence, memory, and quality of life. It 
targeted and changed glucose metabolism in problem areas of the brain. Lastly, it was shown to 
be relatively safe with no significant adverse reactions. With more extensive and consistent 
research, this could offer a viable solution to a very difficult-to-treat condition, improving the 
lives of those who suffer from it and decreasing the amount of time and money spent on 
refractory treatment and multiple hospitalizations. In contrast to many of the conventional 
treatments used today, this treatment seems to target the root of the problem: how the brain is 
processing signals and information and may offer a great treatment for refractory AN in women. 
Although the evidence is limited and more research needs to be done, the effect of DBS on 
outcomes in adolescent and adult women with AN looks promising.  
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Table I. Characteristics of Reviewed Studies, GRADE Profile 
 
 
aShort follow-up times in all 3 studies and no control group in Wang et al1 or Lipsman et al4. 
bSmall sample size and large standard deviations in all 3 studies. 
cInconsistencies (failure of 50% of subjects to improve with treatment) in Lipsman et al4 without sufficient explanation. 
Quality Assessment  
Quality Importance  Downgrade Criteria  
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study/Studies 
Body Weight (BMI) 
3 3 Observational 
 Very 
serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
Serious 
inconsistenciesc No bias likely 
Wang et al1 
Very low Critical Lipsman et al4 
Zhang et al35 
Vital Signs and Return of Menstruation  
1 1 Observational No serious limitations 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies No bias likely Lipsman et al
4 Very low Critical 
Psychological Symptoms (anxiety, depression, ED, OCD, psychoticism, neuroticism, intelligence, memory) 
2 2 Observational 
Very 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
Serious 
inconsistenciesc No bias likely 
 
Wang et al1 
 Very low Important 
Lipsman et al4 
Changes in Brain Glucose Metabolism 
2 2 Observational No serious limitations 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies No bias likely 
Lipsman et al4 Very low Important Zhang et al35 
Safety of DBS 
2 2 Observational Serious limitations 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies No bias likely 
Wang et al1 
 Very low Critical 
Lipsman et al4 
Quality of Life  
2 2 Observational 
Very 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
Serious 
inconsistenciesc No bias likely 
Wang et al1 
 Very low Important 
Lipsman et al4 
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Tables II-III. Summary of Findings 
TABLE II Wang et al1 
 
 
 
Values show mean with (standard deviations) 
aHAMD 
bHAMA 
cWechsler Adult Intelligence Scale-Revised Chines version 
dWechsler Adult Memory Scale-Revised Chinese version 
 
 
TABLE III Lipsman et al4 
 
Outcome Baseline 
Pre-
operativ 
e 
Post-operative (1-2 
months) 
Post-operative (3 
months) 
Post-operative (6 
months) 
Post-operative (9 
months) 
P 
value 
BMI (Mean) 13.7 16.1 14.0 14.7 15.3 16.6  
Adverse Events -- -- 
Reported,a,but most 
related  
to the disease itself 
-- -- --  
HAMD 
(Depression) -- 17.8 (8.2) 13.6 (6.6) 12.5 (6.6) 10.7 (8.4) --  
BDI (Depression) -- 38.8 (23.2) 29.2 (6.2) 25.8 (18.3) 20.2 (20.4) --  
YBOCS (OCD) -- 25.0 (10.9) -- 15.8 (6.2) 13.2 (6.9) --  
BAI (Anxiety) -- 31.2 (18.8) 26.7 (13.9) 29.0 (18.5) 21.7 (14.1) --  
YBC-EDS (ED 
Preoccupations) -- 23.7 (3.4) 22.2 (9.6) 19.7 (7.1) 17.7 (6.9) --  
YCS-EDS (ED 
Rituals) -- 29.3 (3.7) 22.3 (9.9) 22.2 (6.8) 19.0 (9.5) --  
Glucose 
Metabolism     
Decreasedb  
Increasedc   <0.01 
Quality of Life        
Overall  57.3 (25.6) -- -- -- 65.8 (20.1) --  
Among Increased BMI  
Group 
43.0 
(10.0) -- -- -- 60.0 (7.5) --  
Among Unchanged 
BMI 
Group 
71.7 
(30.4) -- -- -- 71.7 (29.1) --  
 
Values show mean with (standard deviations) 
aPain, nausea, pancreatitis, hypokalemia, panic attack, seizure, delirium, hypophosphatemia, QT prolongation, worsening mood  
bAnterior cingulate, medial frontal gyrus, bilateral insula, left caudate, left claustrum, and left cerebellum 
cPosterior cortical regions, right middle and inferior temporal gyrus, left post-central gyrus, right precuneus, right supramarginal gyrus, right inferior parietal lobe, and left cuneus 
 
 
 
 
 
 
 
Outcome Pre-operative Post-operative (1 week) Post-operative (6 months) Post-operative (1 year) P value 
BMI 13.31 (0.53) 13.71 (0.65) 18.90 (1.35) 20.14 (1.38)  
Vital Signs      
Blood Pressure (mmHg) 87.75/63.50 (6.69/4.38) 
87.00/64.25  
(5.13/2.31) 
95.12/68.38  
(3.6/1.77) 
105.75/73.50 
(4.59/1.60)  
Heart Rate (bpm) 52.63 (6.30) 53.25 (5.39) 63.13 (2.53) 72.00 (2.62)  
Temperature (°C)   35.71 (0.31) 35.76 (0.34) 36.05 (0.21) 36.43 (0.10)  
Obsession 8.63 (5.53) 3.88 (3.64) 2.88 (3.14) 2.38 (3.16) 0.01 
Compulsion 7.13 (5.84)  3.38 (3.93) 2.38 (2.77) 2.38 (3.38)  
Depressiona 19.13 (6.45) 9.13 (5.67) 5.38 (3.81) 5.38 (2.72) 0.001 
Anxietyb 18.88 (9.64) 10.38 (10.74) 6.88 (7.04) 3.88 (3.09) 0.003 
Intelligencec 91.25 (2.82) -- 101.50 (5.66) 112.25 (6.65) <0.001 
Memoryd 83.38 (3.62) -- 92.63 (3.81) 96.88 (1.73) <0.003 
